26 June 2020

2019: Building on Success and Launching New Initiatives

Oncode Institute is proud to present the public summary of its second Annual Report.

Vesna de Jong

Vesna de Jong

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.

The report showcases the highlights of Oncode in 2019. Outsmarting cancer is one of the most ambitious missions of our times - one that no single group can complete on its own. That’s why we have joined the forces of 61 research groups across the Netherlands. Our 800+ researchers have access to world class infrastructure, technologies, training, support teams and financial means to support high-risk research projects. Oncode’s scientific community is deliberately set up to promote interdisciplinary research, reduce barriers to collaboration, and foster a culture of openness and sharing.

We invite you to read about how we did that last year and what we are planning for the future.

Click here to read the full report

Other News

LOGO
Cancer Research UK forms strategic alliance with the Oncode Institute
Cancer Research UK, the world’s largest private funder of cancer research, today announces a strategic alliance with Oncode Institute. The five-year partnership is the first under Cancer Research UK’s new innovation organisation, Cancer Research Horizons, as well as being Oncode’s first UK partner. The alliance aims to foster innovation and collaboration between world-leading cancer researchers.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Georgi and david
A new critical regulator of interferon signaling discovered
The group of Oncode Investigator Daniel Peeper (NKI) has published in Nature Communications its discovery of a new regulator of interferon γ (IFNγ signaling. The IFNγ response pathway is associated with response to immunotherapy in cancer.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Sliertjes1
Simmunext: where immunotherapy and chemistry meet
Simmunext is a company name made of three words describing the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. The company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>